酪氨酸激酶2
广告
化学
药物发现
激酶
酪氨酸激酶
信号转导
受体
药理学
计算生物学
生物化学
生物
血小板源性生长因子受体
体外
生长因子
作者
Brian S. Gerstenberger,Catherine M. Ambler,Eric P. Arnold,Mary Ellen Banker,Matthew F. Brown,James D. Clark,Alpay Dermenci,Martin E. Dowty,Andrew Fensome,Susan C. Fish,Matthew M. Hayward,Martin Hegen,Brett D. Hollingshead,John D. Knafels,David W. Lin,Tsung H. Lin,Dafydd R. Owen,Eddine Saiah,Raman Sharma,Felix F. Vajdos
标识
DOI:10.1021/acs.jmedchem.0c00948
摘要
Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, respectively. On the basis of human genetic and emerging clinical data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clinical profile compared to currently approved JAK inhibitors. The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif. With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established. Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clinical candidate PF-06826647 ( 22 ).
科研通智能强力驱动
Strongly Powered by AbleSci AI